Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct celluar signaling pathways

被引:40
|
作者
Reyniers, Lauran [1 ]
Del Giudice, Maria Grazia [2 ]
Civiero, Laura [3 ]
Belluzzi, Elisa [3 ]
Lobbestael, Evy [1 ]
Beilina, Alexandra [4 ]
Arrigoni, Giorgio [5 ,6 ]
Derua, Rita [7 ]
Waelkens, Etienne [7 ]
Li, Yan [8 ]
Crosio, Claudia [2 ]
Iaccarino, Ciro [2 ]
Cookson, Mark R. [4 ]
Baekelandt, Veerle [1 ]
Greggio, Elisa [3 ]
Taymans, Jean-Marc [1 ]
机构
[1] Katholieke Univ Leuven, Lab Neurobiol & Gene Therapy, Dept Neurosci, B-3000 Leuven, Belgium
[2] Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy
[3] Univ Padua, Dept Biol, Padua, Italy
[4] NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA
[5] Univ Padua, Dept Biomed Sci, Padua, Italy
[6] Univ Padua, Prote Ctr, Padua, Italy
[7] Katholieke Univ Leuven, Dept Cellular & Mol Med, Lab Prot Phosphorylat & Prote, Leuven, Belgium
[8] NINDS, Prot Peptide Sequencing Facil, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院; 比利时弗兰德研究基金会;
关键词
LRRK1; LRRK2; Parkinson's disease; protein-protein interactions; signaling networks; REPEAT KINASE 2; PARKINSONS-DISEASE; 14-3-3; BINDING; GENE; MUTATIONS; PHOSPHORYLATION; VARIANTS; HETERODIMERIZATION; DEPHOSPHORYLATION; SUSCEPTIBILITY;
D O I
10.1111/jnc.12798
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Genetic studies show that LRRK2, and not its closest paralogue LRRK1, is linked to Parkinson's disease. To gain insight into the molecular and cellular basis of this discrepancy, we searched for LRRK1- and LRRK2-specific cellular processes by identifying their distinct interacting proteins. A protein microarray-based interaction screen was performed with recombinant 3xFlag-LRRK1 and 3xFlag-LRRK2 and, in parallel, co-immunoprecipitation followed by mass spectrometry was performed from SH-SY5Y neuroblastoma cell lines stably expressing 3xFlag-LRRK1 or 3xFlag-LRRK2. We identified a set of LRRK1- and LRRK2-specific as well as common interactors. One of our most prominent findings was that both screens pointed to epidermal growth factor receptor (EGF-R) as a LRRK1-specific interactor, while 14-3-3 proteins were LRRK2-specific. This is consistent with phosphosite mapping of LRRK1, revealing phosphosites outside of 14-3-3 consensus binding motifs. To assess the functional relevance of these interactions, SH-SY5Y-LRRK1 and -LRRK2 cell lines were treated with LRRK2 kinase inhibitors that disrupt 14-3-3 binding, or with EGF, an EGF-R agonist. Redistribution of LRRK2, not LRRK1, from diffuse cytoplasmic to filamentous aggregates was observed after inhibitor treatment. Similarly, EGF induced translocation of LRRK1, but not of LRRK2, to endosomes. Our study confirms that LRRK1 and LRRK2 can carry out distinct functions by interacting with different cellular proteins. LRRK1 and LRRK2 (leucine-rich repeat kinase) interaction partners were identified by two different protein-protein interaction screens. These confirmed epidermal growth factor receptor (EGR-R) as a LRRK1-specific interactor, while 14-3-3 proteins were LRRK2-specific. Functional analysis of these interactions and the pathways they mediate shows that LRRK1 and LRRK2 signaling do not intersect, reflective of the differential role of both LRRKs in Parkinson's disease.
引用
收藏
页码:239 / 250
页数:12
相关论文
共 50 条
  • [21] LRRK2 protein is a component of Lewy bodies
    Zhu, Xiongwei
    Siedlak, Sandra L.
    Smith, Mark A.
    Perry, George
    Chen, Shu G.
    ANNALS OF NEUROLOGY, 2006, 60 (05) : 617 - 618
  • [22] Detection of high molecular weight LRRK2 protein complexes in a cellular model of LRRK2 neurodegeneration
    Valkimadi, P.
    Antoniou, N.
    Rideout, H.
    MOVEMENT DISORDERS, 2011, 26 : S28 - S29
  • [23] Neuronal death signaling pathways triggered by mutant LRRK2
    Rideout, Hardy J.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2017, 45 : 123 - 129
  • [24] The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation
    Cogo, Susanna
    Ho, Franz Y.
    Tosoni, Elena
    Tomkins, James E.
    Tessari, Isabella
    Iannotta, Lucia
    Montine, Thomas J.
    Manzoni, Claudia
    Lewis, Patrick A.
    Bubacco, Luigi
    Harlin, Marie-Christine Chartier
    Taymans, Jean-Marc
    Kortholt, Arjan
    Nichols, Jeremy
    Cendron, Laura
    Civiero, Laura
    Greggio, Elisa
    BRAIN RESEARCH, 2022, 1778
  • [25] Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle
    Lobbestael, Evy
    Zhao, Jing
    Rudenko, Lakov N.
    Beylina, Aleksandra
    Gao, Fangye
    Wetter, Justin
    Beullens, Monique
    Bollen, Mathieu
    Cookson, Mark R.
    Baekelandt, Veerle
    Nichols, R. Jeremy
    Taymans, Jean-Marc
    BIOCHEMICAL JOURNAL, 2013, 456 : 119 - 128
  • [26] Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1
    Greggio, Elisa
    Lewis, Patrick A.
    van der Brug, Marcel P.
    Ahmad, Rili
    Kaganovich, Alice
    Ding, Jinhui
    Beilina, Alexandra
    Baker, Acacia K.
    Cookson, Mark R.
    JOURNAL OF NEUROCHEMISTRY, 2007, 102 (01) : 93 - 102
  • [27] Protein kinase C showcases allosteric control: activation of LRRK1
    Tovell, Hannah
    Newton, Alexandra C.
    BIOCHEMICAL JOURNAL, 2023, 480 (03) : 219 - 223
  • [28] Anatomical characterization of LRRK2 protein expression in mouse brain
    Melrose, H. L.
    Kent, C. B.
    Taylor, J. P.
    Van Kampen, J. M.
    Farrer, M. J.
    MOVEMENT DISORDERS, 2006, 21 : S555 - S556
  • [29] Validation of protein phosphatases that regulate the LRRK2 phosphorylation cycle
    Drouyer, M.
    Emanuele, M.
    Lefebvre, R.
    Cailliau-Maggio, K.
    Martoriati, A.
    Comptdaer, T.
    Semaille, P.
    Mutez, E.
    Sibran, W.
    Wolkoff, N.
    Lobbestael, E.
    Bolliger, M.
    Baekelandt, V.
    Nichols, J.
    Chartier-Harlin, M. C.
    Taymans, J. M.
    MOVEMENT DISORDERS, 2018, 33 : S771 - S771
  • [30] LRRK2 mRNA and protein expression in Parkinson's disease cases with LRRK2 G2019S mutation
    Sharma, S.
    Bandopadhyay, R.
    Kingsbury, A. E.
    Lashley, T. C.
    Lees, A. J.
    Revesz, T.
    Wood, N. W.
    Holton, J. L.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2009, 35 : 27 - 28